MMP8 peptide (Carboxyterminal end) (ab41065)

Product Name 

MMP8 peptide (Carboxyterminal end)

Product type 

Proteins and Peptides

Peptide 

Synthetic peptide MMP8.


This peptide was used as an immunogen for ab38990 - MMP8 antibody - Carboxyterminal end.

Specificity 

We have a range of domain specific antibodies for this target. For a full list please see all MMP8 antibodies

Tested applications 
(see key)

ELISA, WB

Application notes 
(see key)

Recommended dilutions
ELISA: Use at an assay dependent dilution. WB: Use at an assay dependent dilution. This peptide can be used with studies using ab38990. Dilution optimised using Chromogenic detection. Not yet tested in other applications. Optimal dilutions/concentrations should be determined by the end user.

Research areas 

Cardiovascular >> Atherosclerosis >> Vascular Inflammation >> Leukocyte recruitment >> Other
Cancer >> Tumor biomarkers >> Enzymes >> MMPs
Cell Biology >> Proteolysis / Ubiquitin >> Proteolytic enzymes >> Metalloprotease >> MMPs
Cancer >> Invasion/microenvironment >> ECM >> Extracellular matrix >> MMPs
Signal Transduction >> Cytoskeleton / ECM >> Extracellular Matrix >> ECM Enzymes >> MMP
Cardiovascular >> Angiogenesis >> Adhesion / ECM >> Matrix Metalloproteinases >> MMP

Relevance 

Matrix Metalloproteinase 8 (MMP8) is also known as neutrophil collagenase and collagenase 2. MMP8 degrades fibrillar collagens types I, II, III, aggrecan, serpins and alpha 2 macroglobulin. All collagenases cleave fibrillar collagens at one specific site resulting in generation of N terminal three quarter and C terminal one quarter fragments, which then denature to gelatin at body temperature. The substrate specificity of collagenases is variable: MMP1 degrades type III collagen more efficiently than type I or type II collagen, whereas MMP8 is more potent in degrading type I collagen than type III or type II collagen. MMP13, in turn degrades type II collagen 6 fold more efficiently than type I and type II collagens and displays almost 50 fold stronger gelatinolytic activity than MMP1 and MMP8. MMP8 is very similar to MMP1, sharing 57 % amino acid identity. Most cell types do not produce MMP8. Until recently, it was thought that MMP8 was produced exclusively by neutrophils, but it has also been detected in other cell types including arthritic chondrocytes and gingival fibroblasts. The human MMP8 gene has the chromosomal location of 11q22.2-22.3. MMP8 is heavily glycosylated, and the zymogen has a mass of 85 Kd. The zymogen is quickly activated to the 64 Kd form, and this breaks down to a cascade of active forms.

Purity 

>95% by SDS-PAGE

Storage buffer 

Preservative: None
Constituents: 0.001% Tween 20, 30mM HEPES, 2mM EDTA, 150mM Sodium chloride, pH 6.75

Form 

Liquid

Concentration 

1.000 mg/ml

Storage instructions 

Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Customer reviews (feedback) regarding MMP8 peptide (Carboxyterminal end)

Customer FAQs regarding MMP8 peptide (Carboxyterminal end)

Protocols for MMP8 peptide (Carboxyterminal end)

Price and availability of products related to MMP8 peptide (Carboxyterminal end)

MMP8 peptide (Carboxyterminal end) - related products: